CVE:MFSMedifocus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medifocus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.0050 -327,141.00 (-100.00 %) (As of 04/9/2020 04:00 PM ET) Add Compare Share Today's RangeC$0.01Now: C$0.01▼C$0.0150-Day RangeC$0.01MA: C$0.01▼C$0.0152-Week RangeC$0.01Now: C$0.01▼C$0.03Volume25,000 shsAverage Volume104,118 shsMarket CapitalizationC$924,920.00P/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartEarningsHeadlinesSocial Media Medifocus Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the United States. The company owns technology platforms, including Endo-thermotherapy platform, a catheter-based focused heat technology platform that utilizes natural body openings to deliver microwave thermotherapy to the diseased sites; and Adaptive Phased Array (APA) Microwave Focusing platform, which directs focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. It also offers Prolieve Thermodilatation system, a medical device based on endo-thermotherapy for the treatment of benign prostatic hyperplasia. In addition, the company is developing APA 1000, a minimally invasive breast cancer treatment system, which is in pivotal Phase-III clinical trials. The company has a license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy technology for the treatment of cancers and other diseases. Medifocus Inc. has a patent license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy for the treatment of cancers and other diseases. The company is based in Columbia, Maryland.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Medifocus. Previous Next 2.5 Community Rank Outperform VotesMedifocus has received 54 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMedifocus has received 56 “underperform” votes. (Add your “underperform” vote.)Community SentimentMedifocus has received 50.91% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Medifocus and other stocks. Vote “Outperform” if you believe MFS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MFS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMedifocus does not currently pay a dividend.Dividend GrowthMedifocus does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medifocus insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifocus is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifocus is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:MFS Previous Symbol CUSIPN/A CIKN/A Webhttp://www.medifocusinc.com/ Phone+1-905-3197070Debt Debt-to-Equity RatioN/A Current Ratio0.04 Quick Ratio0.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$2.23 million Price / Sales0.41 Cash FlowC$0.00 per share Price / Cash Flow5.00 Book ValueC($0.07) per share Price / Book-0.08Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees7 Outstanding Shares184,984,000Market CapC$924,920.00 Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable Receive MFS News and Ratings via Email Sign-up to receive the latest news and ratings for MFS and its competitors with MarketBeat's FREE daily newsletter. TSXV:MFS Rates by TradingView Medifocus (CVE:MFS) Frequently Asked Questions When is Medifocus' next earnings date? Medifocus is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Medifocus. Has Medifocus been receiving favorable news coverage? Media stories about MFS stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medifocus earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutMedifocus. Who are some of Medifocus' key competitors? Some companies that are related to Medifocus include Revive Therapeutics (RVV), IBEX Technologies (IBT), Amplia Therapeutics (ATX), BPH Energy (BPH), Netscientific (NSCI), SalvaRx Group (SALV), Physiomics (PYC), Cotinga Pharmaceuticals (COT), Pacgen Life Science (PBS), Port Erin Biopharma Investments (PEBI), ImmunoCellular Therapeutics (IMUC), Motif Bio (MTFB), ValiRx (VAL), AngioSoma (SOAN) and Abattis Bioceuticals (ATTBF). What other stocks do shareholders of Medifocus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medifocus investors own include Relypsa (RLYP), Chevron (CVX), BP Prudhoe Bay Royalty Trust (BPT), Sangamo Therapeutics (SGMO), Regeneron Pharmaceuticals (REGN), Onconova Therapeutics (ONTX), Intec Pharma (NTEC), FireEye (FEYE) and Axon Enterprise (AAXN). Who are Medifocus' key executives? Medifocus' management team includes the following people: Dr. William W. Jow, CEO, Pres & Director (Age 61)Mr. Mirsad Jakubovic C.A., M.B.A., Chief Financial Officer (Age 57)Mr. John Mon, VP of Regulatory Affairs & Product Devel. (Age 66)Mr. Douglas Liu, VP of Fin. (Age 55)Dr. Stuart E. Katz M.D., VP of Operations What is Medifocus' stock symbol? Medifocus trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MFS." How do I buy shares of Medifocus? Shares of MFS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Medifocus' stock price today? One share of MFS stock can currently be purchased for approximately C$0.01. How big of a company is Medifocus? Medifocus has a market capitalization of C$924,920.00 and generates C$2.23 million in revenue each year. Medifocus employs 7 workers across the globe. View additional information about Medifocus. What is Medifocus' official website? The official website for Medifocus is http://www.medifocusinc.com/. How can I contact Medifocus? Medifocus' mailing address is The Exchange Tower Suite 1800, 130 King Street West, PO Box 427, TORONTO, ON M5X 1E3, Canada. The company can be reached via phone at +1-905-3197070. This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: How to Trade Using Analysts Ratings
